Introduction
============

Cancer is still considered to be a major challenge for modern medicine and a major public health problem worldwide.[@b1-cmar-10-2279] Tumor-specific markers can be useful for monitoring and evaluating tumor progression and therapeutic efficacy. However, there is still a shortage of highly sensitive and specific markers for assessing cancer progression and prognosis.[@b2-cmar-10-2279] Therefore, it is necessary for decision-making concerning clinical therapy to figure out an effective pretreatment parameter that can be used to evaluate survival probability and prognosis of cancer patients.

Phospho-histone-H3 (PHH3) is a core histone protein, which in its phosphorylated state forms the principal constituents of eukaryotic chromatin, with histone H3 being phosphorylated at serine (Ser) 10 or Ser28 as well as its phosphorylation of Ser10 being strongly correlated with the late G2 to M-phase transition in mammalian mitotic cells.[@b3-cmar-10-2279] On the basis of previous research, a few cell line- and animal model-based researches have displayed an increase in phosphorylation of histone H3 at Ser10 (H3S10ph), the only histone marker that is involved in carcinogenesis and cellular transformation.[@b4-cmar-10-2279]--[@b7-cmar-10-2279] Also, earlier in vitro studies have suggested that a higher level of H3S10ph alone directly participated in cellular transformation.[@b5-cmar-10-2279] PHH3 has long been accepted as a cellular proliferation marker in a large variety of cancers, and it was revealed to be of prognostic value in several recent studies.[@b8-cmar-10-2279]--[@b10-cmar-10-2279] For instance, PHH3 expression is elevated in gliomas tissues, and patients with high PHH3 expression have a shorter overall survival (OS) compared with patients with lower expression levels of PHH3.[@b8-cmar-10-2279] Elevated PHH3 expression is also detected in prostate carcinoma tissues and is strongly correlated with an advanced clinical stage.[@b9-cmar-10-2279] In breast cancer, increased PHH3 expression is correlated with an lymph vessel invasion.[@b10-cmar-10-2279] However, the association between elevated PHH3 expression and prognosis has not been identified in patients with gastrointestinal stromal tumors.[@b11-cmar-10-2279] Therefore, we conducted this meta-analysis to summarize the global findings from analyses of PHH3 expression as a predictive indicator of clinical results in cancer patients.

Patients and methods
====================

Search strategy
---------------

We performed a network search using PubMed, Web of Science, Embase, and Cochrane Library for original articles that analyzed the prognostic value of PHH3 in various cancers, with the last search update on February 1, 2018. The search strategy included the following keywords combined with "phospho-histone-H3:" "PHH3", "neoplasm", "cancer", "prognostic", and "prognosis". Furthermore, additional eligible studies were collected by a manual search for relevant research from reference lists.

Selection criteria
------------------

The studies were considered eligible if they met all the following criteria: 1) studies that evaluated the relationship of PHH3 expression in cancer patients with detailed information about OS, disease-free survival (DFS), or recurrence-free survival (RFS); 2) HRs and 95% CIs, raw data, or survival curves were reported in the article; and 3) the articles were written in English or Chinese. Articles were excluded based on the following criteria: 1) meeting abstract, review or laboratory articles, as well as case studies or letters; 2) articles that described the survival outcome of other indicators; 3) duplicate publications; and 4) animal studies.

Quality assessment
------------------

To control the quality of the research, the Newcastle--Ottawa scale, ranging from 0 to 9 stars,[@b12-cmar-10-2279] was used to assess the quality of the eligible papers. Studies with more than six stars were considered high quality. Two authors (Qian Hao and Yujiao Deng) performed the assessment independently, and any disagreement was resolved by discussion.

Data extraction
---------------

Two independent reviewers (Qian Hao and Cong Dai) extracted the details of included studies using a standardized form, and any disagreements were resolved through discussion with a third reviewer (Zhijun Dai). The following information was recorded: the first author's name, year of publication, number of patients, patient source, tumor types, PHH3 assessment method, prognostic outcomes, analytical method, and HR with the corresponding 95% CI.

Statistical analysis
--------------------

Statistical analyses were conducted using STATA version C14.0 (Stata Corporation, College Station, TX, USA). The HRs with their 95% CIs were used for evaluating the strength of the correlations between PHH3 and the survival outcomes. We evaluated the study heterogeneity (*I*[@b2-cmar-10-2279]) by chi-squared test. All statistical tests were two-sided, and the significance level was set at 0.05. The fixed effects model was used when no obvious heterogeneity was observed among the included studies (*I*[@b2-cmar-10-2279]\<50%), otherwise the random effects model was selected to perform the meta-analysis. Subgroup analyses were conducted to investigate the potential factors of heterogeneity. Publication bias was estimated by Begg's funnel plot and Egger's test. Sensitivity analysis was performed by sequential omission of each study.

Results
=======

Characteristics of included studies
-----------------------------------

Based on the study design, we initially searched a total of 410 articles. After duplicates were removed, 216 articles remained. Hundred and seventy-four articles qualified for review after we screened titles and abstracts. Subsequently, 122 studies were assessed by screening the full text, of which 103 articles were excluded (Table S1). Finally, 19 studies, published between 2011 and 2017, were included in this meta-analysis as shown in [Figure 1](#f1-cmar-10-2279){ref-type="fig"}. The Newcastle--Ottawa scores of these studies ranged between 6 and 8. The total number of patients included were 4803, ranging between 27 and 637 patients per study. The main characteristics of the 19 articles were extracted and are summarized in [Table 1](#t1-cmar-10-2279){ref-type="table"}. The patients were from People's Republic of China,[@b8-cmar-10-2279],[@b13-cmar-10-2279],[@b14-cmar-10-2279] Korea,[@b15-cmar-10-2279] Norway,[@b10-cmar-10-2279],[@b16-cmar-10-2279]--[@b18-cmar-10-2279] India,[@b19-cmar-10-2279] Germany,[@b9-cmar-10-2279],[@b20-cmar-10-2279] the United Kingdom,[@b21-cmar-10-2279],[@b22-cmar-10-2279] the United States of America,[@b11-cmar-10-2279],[@b23-cmar-10-2279] New Zealand,[@b24-cmar-10-2279] Sweden,[@b25-cmar-10-2279] Australia,[@b26-cmar-10-2279] and Italy.[@b27-cmar-10-2279] The types of carcinoma included glioma, neuroblastoma, gastric cancer, gastrointestinal stromal tumor, Merkel cell carcinoma, cutaneous melanoma, uterine smooth muscle tumor, endometrial cancer, adrenocortical carcinoma, prostate cancer, and breast cancer. Immunohistochemical staining was used to determine the level of PHH3 expression.

Association of PHH3 expression with OS in human cancer
------------------------------------------------------

Twelve studies comprising 1259 cancer patients were included in the survival analysis. The pooled HR was 2.66 (95% CI=1.74--4.08, *P*\<0.001; [Figure 2](#f2-cmar-10-2279){ref-type="fig"} and [Table 2](#t2-cmar-10-2279){ref-type="table"}). High expression of PHH3 was significantly related to poor OS of cancer patients. Due to the emergence of clear heterogeneity in this study (*I*[@b2-cmar-10-2279] =74.5%, *P*\<0.001; [Table 2](#t2-cmar-10-2279){ref-type="table"}), a subgroup analysis was conducted to explore the source of heterogeneity further. The subgroups included tumor types, ethnicity, and HR estimate ([Table 2](#t2-cmar-10-2279){ref-type="table"}). High PHH3 expression was significantly associated with reduced OS in breast cancer (HR=5.66, 95% CI=2.72--11.78, *P*\<0.001) and urogenital tumors (HR=3.01, 95% CI=1.78--5.09, *P*\<0.001), but not with nervous system tumors (HR=1.58, 95% CI=0.76--3.28, *P*=0.226), digestive system tumors (HR=1.57, 95% CI=0.73--3.35, *P*=0.247), or cutaneous tumors (HR=2.99, 95% CI=0.85--10.56, *P*=0.089). There was clear heterogeneity in nervous system tumors (*I*[@b2-cmar-10-2279]=69.4%, *P*=0.071) and digestive system tumors (*I*[@b2-cmar-10-2279]=56.6%, *P*=0.129), while no obvious heterogeneity was found in other tumor types. Subgroup analysis showed that the correlation between OS and PHH3 expression did not differ between ethnicities (Asian: HR=1.98, 95% CI=1.08--3.63, *P*=0.026; Caucasian: HR=3.01, 95% CI=1.87--4.85, *P*\<0.001) and HR estimates (multivariate analysis: HR=3.17, 95% CI=1.66--6.04; univariate analysis: HR=1.93, 95% CI=1.31--2.82).

Association of PHH3 expression with DFS and RFS
-----------------------------------------------

Four studies comprising 777 patients were included in determining the relationship between elevated PHH3 expression and DFS. Correspondingly, five studies involving 1496 patients were included for determining the association between PHH3 overexpression and RFS. The pooled outcome indicated that high expression levels of PHH3 might imply poor DFS (HR=3.40; 95% CI=1.47--7.87, *P*=0.004; [Figure 3](#f3-cmar-10-2279){ref-type="fig"} and [Table 2](#t2-cmar-10-2279){ref-type="table"}) and RFS (HR=2.80; 95% CI=1.61--4.85, *P*\<0.001; [Figure 4](#f4-cmar-10-2279){ref-type="fig"} and [Table 2](#t2-cmar-10-2279){ref-type="table"}). Furthermore, significant heterogeneity was noted among the studies (DFS: *I*[@b2-cmar-10-2279] =67.4%, *P*=0.027; RFS: *I*[@b2-cmar-10-2279] =72.6%, *P*=0.006). However, we did not conduct subgroup analyses to determine sources of heterogeneity because of the small number of studies.

Sensitivity analyses and publication bias
-----------------------------------------

In order to determine whether an individual study had a significant influence on pooled HR and to confirm the stability and reliability of HR estimates, all the studies were sequentially removed. We found that the pooled HRs were not significantly influenced by any single study ([Figure 5](#f5-cmar-10-2279){ref-type="fig"}). Both the Begg's and Egger's tests were performed to assess if any publication bias existed in the included studies. The funnel plot ([Figure 6](#f6-cmar-10-2279){ref-type="fig"}) was asymmetrical. Begg's test (*P*=0.193) revealed no publication bias among the 12 eligible studies, while Egger's test (*P*=0.002) showed a clear bias.

Discussion
==========

PHH3, a chief protein component of nucleosomes in eukaryotic cells, is a less extensively studied proliferation factor. The clear and contrast-rich staining of PHH3 is easily assessed, with high inter-observer reproducibility, making it the subject of intense research in recent years.[@b28-cmar-10-2279],[@b29-cmar-10-2279] PHH3 has been found to be an independent prognostic factor in meningioma, cutaneous melanoma, and gastric cancer.[@b18-cmar-10-2279],[@b20-cmar-10-2279],[@b30-cmar-10-2279],[@b31-cmar-10-2279] We conducted this meta-analysis to mitigate sample size problems of individual studies and enhance their statistical power. Our study is the first meta-analysis to summarize research on PHH3 and its prognostic role in various types of cancer.

In this meta-analysis, we analyzed 19 studies including 4803 patients, with OS data from 12 studies, DFS data from 4 studies, and RFS data from 5 studies, which revealed that a high expression of PHH3 was correlated with poor OS, DFS, and RFS and significantly associated with a reduced OS in patients with breast cancer and urogenital tumors. Thus, PHH3 expression may be considered as a potential prognostic factor for cancer patients. It is well known that Ki-67 is commonly used to assess cell proliferation. However, according to Takahashi et al and Brenner et al, PHH3 expression was an independent factor for poor prognosis and an improved mitotic marker in gastric cancer and endometrial tissues compared to Ki-67.[@b31-cmar-10-2279],[@b32-cmar-10-2279] Likewise, some previous studies have noted that PHH3 is an excellent predictability marker of survival in long- and short-term follow-up.[@b15-cmar-10-2279],[@b24-cmar-10-2279],[@b25-cmar-10-2279] Therefore, we collected and analyzed the results of several studies and found that PHH3 is a novel, useful proliferation marker that can be used as a prognostic indicator in astrocytoma, melanoma, prostate carcinoma, pituitary adenoma, and breast cancer.[@b25-cmar-10-2279],[@b28-cmar-10-2279],[@b29-cmar-10-2279],[@b33-cmar-10-2279]--[@b36-cmar-10-2279] PHH3 may also be a prognostic marker in various other types of cancer. To further analyze the role of PHH3 in different cancers, a subgroup analysis was performed. PHH3 expression was found to be statistically associated with breast, gynecological, cutaneous, and urogenital tumors.

Through the subgroup analysis, we found that the heterogeneity of our study originated from tumors of the nervous and digestive systems. Additionally, PHH3 doesn't have standard testing methods and it's also not routinely utilized. Its practical utility is limited so far, different phosphorylation sites (Ser10 and Ser28) and measurement units were used in these studies in different labs, detection assays, antibodies, and thresholds for positivity, given that it may cause significant discrepancies and biases in our studies. Furthermore, we conducted subgroup analyses of study region and analysis method; however, no significant differences were detected. It is important to note that there was a publication bias, suggesting that large-scale investigations are required. An inadequate number of included studies analyzed the OS, DFS, and RFS rates, with controversial conclusions. Overall, our meta-analysis supports the conclusion that PHH3 may be a predictive biomarker of OS, DFS, and RFS. Thus, further research is necessary to evaluate the relationship between overexpression of PHH3 and outcomes in human cancers.

Moreover, we found that some studies have identified a close correlation between PHH3 and mitotic cell condensation.[@b37-cmar-10-2279],[@b38-cmar-10-2279] Immunohistochemical staining of PHH3 has suggested that modification occurs almost exclusively in actively proliferating cells during M-phase, not during apoptosis.[@b39-cmar-10-2279] From a clinical standpoint, PHH3 immunostaining has been validated in pulmonary melanoma, neuroendocrine carcinomas, and pancreatic cancer. Several previous studies have measured PHH3 levels among different types of cancers. Studies suggested that PHH3 index increased with higher grade of tumor, including cancers of breast, ovarian, melanoma, and meningioma.[@b20-cmar-10-2279],[@b29-cmar-10-2279],[@b40-cmar-10-2279]--[@b43-cmar-10-2279] Therefore, PHH3 staining not only has prognostic value but also supports tumor grading by facilitating mitotic counting. PHH3 staining can be easily identified and can minimize inter-observer and inter-laboratory technical variations. In addition, one study suggested that the PHH3 index is a more sensitive measure of mitotic activity in Merkel cell carcinoma than the hematoxylin and eosin (H&E)-stained mitotic count index. Thus, it is believed to be a useful complementary diagnostic tool for standard H&E mitotic counts. Another study confirms that PHH3 was a better proliferation marker than Ki-67 due to its high reproductivity of immunohistochemistry, accuracy, and consistency among raters in breast cancer.[@b15-cmar-10-2279] Finally, the "true" negative resection margin in gastric cancer has reportedly been determined using the distance-dependent association of PHH3 with clinical parameters. Therefore, PHH3 could be helpful in limiting the extent of resection and preventing post-surgical locoregional recurrence of the disease.[@b19-cmar-10-2279]

Generally, PHH3 expression levels are helpful in predicting the prognosis of different cancers, and PHH3 staining can be a useful complementary tool to routine methods in grading and determining "true" negative resection margins.

Conclusion
==========

In summary, we found that increased expression of PHH3 indicated poor survival outcomes in patients with cancer, and therefore, PHH3 is a potential novel prognostic indicator in cancer patients.
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![Sensitivity analysis of pooled HRs on the association between PHH3 expression and OS.\
**Abbreviations:** OS, overall survival; PHH3, phospho-histone-H3.](cmar-10-2279Fig5){#f5-cmar-10-2279}
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###### 

Main characteristics of all studies included in the meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                           Year   Patient source               Number of patient   Tumor types      Specimen   Method   PHH3 high expression (%)   Median (range) follow-up (month)   Outcome   M/U   HR (95% CI)          NOS
  -------------------------------------- ------ ---------------------------- ------------------- ---------------- ---------- -------- -------------------------- ---------------------------------- --------- ----- -------------------- -----
  Kim et al[@b15-cmar-10-2279]           2017   Korea                        218                 BC               Tissue     IHC      40.30                      46                                 DFS       U     8.90 (1.07--74.0)    9

  Chow et al[@b13-cmar-10-2279]          2017   People's Republic of China   55                  USMT             Tissue     IHC      --                         65.5                               OS        M     2.71 (1.06--6.94)    7

  Zhu et al[@b8-cmar-10-2279]            2016   People's Republic of China   61                  Gliomas          Tissue     IHC      51.67                      44.3                               OS        M     1.19 (1.01--1.41)    8

  Winther et al[@b16-cmar-10-2279]       2016   Norway                       160                 Meningiomas      Tissue     IHC      --                         --                                 RFS       M     3.05 (1.46--6.58)    7

  Khan et al[@b19-cmar-10-2279]          2016   India                        101                 GC               Tissue     IHC      58.42                      --                                 OS\       U\    2.15 (1.07--4.28)\   8
                                                                                                                                                                                                    DFS       U     1.44 (0.61--3.41)    

  Goltz et al[@b9-cmar-10-2279]          2015   Germany                      637                 PC               Tissue     IHC      --                         51                                 RFS       U     1.84 (1.09--3.11)    8

  Iwasaki et al[@b21-cmar-10-2279]       2015   UK                           27                  MCC              Tissue     IHC      --                         42                                 OS        M     7.47 (1.41--39.61)   6

  Ramani et al[@b22-cmar-10-2279]        2015   UK                           80                  Neuroblastomas   Tissue     IHC      30.00                      121.3                              OS        M     2.60 (1.10--5.80)    8

  Alkhasawneh et al[@b11-cmar-10-2279]   2015   USA                          50                  GSTS             Tissue     IHC      34.00                      56.4                               OS        U     0.97 (0.36--2.62)    7

  Gerring et al[@b24-cmar-10-2279]       2015   New Zealand                  108                 BC               Tissue     IHC      --                         85                                 OS        M     4.35 (2.17--8.71)    7

  Olar et al[@b23-cmar-10-2279]          2015   USA                          363                 Meningiomas      Tissue     IHC      15.42                      --                                 RFS       U     1.03 (1.02--1.05)    8

  Duregon et al[@b27-cmar-10-2279]       2014   Italy                        48                  AC               Tissue     IHC      --                         40                                 OS        U     2.22(1.0--5.0)       6

  Xu[@b14-cmar-10-2279]                  2014   China                        52                  PC               Tissue     IHC      94.23                      --                                 OS        M     5.43 (1.24--23.80)   6

  Klintman et al[@b25-cmar-10-2279]      2013   Sweden                       221                 BC               Tissue     IHC      30.77                      --                                 DFS       U     2.40 (1.40--4.30)    8

  Gudlaugsson et al[@b17-cmar-10-2279]   2013   Norway                       237                 BC               Tissue     IHC      35.44                      --                                 RFS\      M\    10.6 (4.4--25.6)\    8
                                                                                                                                                                                                    DFS       M     8.9 (3.4--23.5)      

  Ladstein et al[@b18-cmar-10-2279]      2012   Norway                       338                 CNM              Tissue     IHC      74.85                      61.5                               OS        M     1.90 (1.04--3.36)    9

  Brunner et al[@b26-cmar-10-2279]       2012   Australia                    99                  EC               Tissue     IHC      48.48                      72                                 OS        M     5.9 (1.7--31.4)      8

  Gudlaugsson et al[@b10-cmar-10-2279]   2011   Norway                       240                 BC               Tissue     IHC      35.00                      117                                OS        M     9.6 (3.1--29.9)      9

  Kim et al[@b20-cmar-10-2279]           2007   Germany                      99                  Meningiomas      Tissue     IHC      --                         42                                 RFS       M     1.07 (1.06--1.10)    8
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

'--' unobtainable data.

**Abbreviations:** AC, adrenocortical carcinoma; BC, breast cancer; CNM, cutaneous nodular melanoma; DFS, disease-free survival; EC, endometrial carcinoma; GC, gastric cancer; GSTS, gastrointestinal stromal tumors; IHC, immunohistochemistry; M, multivariate; MCC, Merkel cell carcinoma; NOS, Newcastle--Ottawa scale; OS, overall survival; PC, prostate carcinoma; PHH3, phospho-histone-H3; RFS, recurrence-free survival; U, univariate; USMT, uterine smooth muscle tumor.

###### 

Main meta-analysis results

  Analysis                 No. of studies   No. of patients   Model    HR (95% CI)          *P*-value   Heterogeneity   Publication bias           
  ------------------------ ---------------- ----------------- -------- -------------------- ----------- --------------- ------------------ ------- -------
  OS                       12               1259              Random   2.66 (1.74--4.08)    0.000       74.5            0.000              0.047   0.000
  Tumor type               --               --                --       --                   --          --              --                 --      --
  Nervous system tumor     2                141               Random   1.58 (0.76--3.28)    0.226       69.4            0.071              --      --
  Digestive system tumor   2                151               Random   1.57 (0.73--3.35)    0.247       39.4            0.199              --      --
  Cutaneous tumor          2                365               Random   2.99 (0.85--10.56)   0.089       56.6            0.129              --      --
  Breast cancer            2                348               Random   5.66 (2.72--11.78)   0.000       26.7            0.243              --      --
  Urogenital tumor         4                254               Random   3.01 (1.78--5.09)    0.000       0.00            0.567              --      --
  Ethnicity                --               --                --       --                   --          --              --                 --      --
  Asian                    4                269               Random   1.98(1.08--3.63)     0.026       66.6            --                 --      --
  Caucasian                8                990               Random   3.01(1.87--4.85)     0.000       51.0            --                 --      --
  HR estimate              --               --                --       --                   --          --              --                 --      --
  Multivariate analysis    7                1033              Random   3.17 (1.66--6.04)    0.000       81.8            0.000              --      --
  Univariate analysis      5                226               Random   1.93 (1.31--2.82)    0.001       74.5            0.000              --      --
  DFS                      4                777               Random   3.40 (1.47--7.87)    0.004       67.4            0.027              --      --
  RFS                      5                1496              Random   2.80 (1.61--4.85)    0.000       72.6            0.006              --      --

**Note**

'--' unobtainable data.

**Abbreviations:** DFS, disease-free survival; OS, overall survival; RFS, recurrence-free survival.

[^1]: These authors contributed equally to this work
